Topas Therapeutics GmbH
Topas Therapeutics is developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. Several proprietary programs are in R&D. The lead one is in an orphan disease and is expected to enter the clinic in 2019. Topas has a multi-year research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, a multi-year agreement with Boehringer Ingelheim in the field of anti-drug antibodies and a co-development agreement with Evotec for a Type 1 diabetes program. The Company is backed by a group of highly successful life sciences investors.
About Topas Therapeutics GmbH:
|Field of Activity||Developing new therapeutic solutions for autoimmune diseases, allergies and anti-drug antibodies by leveraging the liver’s natural immunology capabilities.|
|Ownership Structure and Financing||Series A in 2016 (€14 million); additional €4 million in 2017. Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund|
|Partners||Eli Lilly and Company – antigen-specific tolerance induction Boehringer Ingelheim – anti-drug antibodies
Evotec – co-development for Type 1 diabetes program
|Technology||Topas’ technology platform harnesses the natural mechanisms of the liver to promote immune tolerance to blood borne antigens. Identified internal as well as external antigens, known to cause undesired effects, are coupled as peptides to Topas Particle Conjugates (TPCs)
which mimic such blood borne antigens and are taken up by liver sinusoidal endothelial cells (LSECs). LSECs present these antigens to T cells under anti-inflammatory conditions conducive to the induction of tolerogenic regulatory T cells – pivotal for immune tolerance.
|Products/Services||Orphan disease (expected to enter the clinic in 2019), ADA-1 (in vivo POC), Type 1 diabetes (in vivo POC), Celiac disease (discovery), Multiple sclerosis (to be partnered)|
|Unique Selling Point||First firm to leverage the liver’s natural and powerful tolerance induction capabilities: Induces immune tolerance by targeting liver sinusoidal endothelial cells.|
|Date of Incorporation||2013|
|Number of Employees||12|
|Telephone||+49 40 47196-320|
Topas Therapeutics GmbH
Falkenried 88, Haus A